Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Biography
Dr. Zhu is an Assistant Professor of Medicine whose clinical and research expertise focuses on cardio-oncology and cardio-immunology. She specializes in the cardiovascular care of patients undergoing therapies for cancer, with a particular focus on the effects of immunotherapies on the heart. She received a bioengineering degree from MIT, medical degree from Case Western Reserve University, and completed clinical cardiology fellowship and internal medicine residency training at Stanford University School of Medicine. Dr. Zhu’s laboratory focuses on myocarditis, cardiac inflammation, and the effects of cancer therapeutics on the cardiovascular system. Her current research employs clinical data, bio-banked samples, and in vivo/in vitro preclinical models in combination with single-cell technologies to study immune-based toxicities in the heart. Dr. Zhu's clinic sees cardio-oncology and cardio-immunology patients and her lab focuses on devising new methods for minimizing cardiovascular complications in the cancer and autoimmune patient populations.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: National Board of Echocardiography, Adult Echocardiography (2019)
- Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2020)
- Board Certification, American College of Cardiology/ABIM, Cardiovascular Disease (2020)
- Fellowship: Stanford University Cardiovascular Medicine Fellowship (2020) CA
- Board Certification, Society of Cardiovascular Computer Tomography (SCCT), Cardiac CT (2019)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2017)
- Residency: Stanford University Internal Medicine Residency (2017) CA
- Medical Education: Case Western Reserve School of Medicine (2014) OH
- Residency, Stanford University, Internal Medicine (2017)
- Doctor of Medicine, Case Western Reserve University School of Medicine, Medicine (2014)
- Bachelor of Science, Massachusetts Institute of Technology (MIT), Biological Engineering (2009)
Honors & Awards
- Alpha Omega Alpha (AOA) Member, Alpha Omega Alpha (AOA) (2014)
- American Federation of Aging Research (AFAR) Grant Recipient, American Federation of Aging Research (AFAR) (2010)
- Gerald Reaven Basic Science Research Award, Stanford University (2020)
- Irwin H. Lepow Research Award, Irwin H. Lepow Research Foundation (2011)
- Melvin L. Marcus Early Career Investigator Award Finalist, American Heart Association (AHA) - Basic Cardiovascular Sciences (BCVS) (2021)
- Myron F. Kanter and Lawrence J. Kanter Endowment Fund Award, Myron F. Kanter and Lawrence J. Kanter Foundation (2014)
- NIH F32 Ruth Kirschstein National Research Service Award Grant, National Institute of Health (NIH) (2019)
- NIH K08 Mentored Clinical Scientist Research Career Development Award, National Institute of Health (NIH) (2022-)
- NIH Loan Repayment Award, National Institute of Health (NIH) (7/2019)
- Sanofi Innovation Awards (iAwards), Sanofi (2019-2021)
- Sarnoff Cardiovascular Research Foundation Fellowship, Sarnoff Cardiovascular Foundation (2012-2013)
- Sarnoff Scholar Career Development Award, Sarnoff Cardiovascular Foundation (2020)
- Stanford Cancer Institute (SCI) Innovation Award, Stanford Cancer Institute (SCI) (2019)
- Stanford Cardiovascular Institute (CVI) Manuscript Award, Stanford Cardiovascular Institute (CVI) (1/2023)
- Stanford Cardiovascular Institute (CVI) Seed Grant, Stanford Cardiovascular Institute (CVI) (9/2023)
Memberships
- Assistant Editor, JACC: CardioOncology (2020 - Present)
- Committee Member, AHA Statement on Preclinical Models in Cardio-Oncology Writing Group (2020 - Present)
- Cardio-Oncology Subcommittee Member, American Heart Association (AHA) (2019 - Present)
- Committee Member, American College of Cardiology Cardio-Oncology - California Chapter (2020 - Present)
- Member, Society of Cardiovascular Computed Tomography (SCCT) (2019 - Present)
- Member, American Society of Echocardiography (2019 - Present)
Administrative Appointments
- Co-Director, Stanford Immune Related Toxicity Working Group (2022 - Present)
- Director, Stanford Translational Cardio-Oncology (2022 - Present)
Publications
-
Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors.
Qian, Y., Zhu, H., Pollom, E. L., Durkee, B. Y., Chaudhuri, A. A., Gensheimer, M. F., … Loo, B. W. (2017). Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. Practical Radiation Oncology. -
Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program.
Morrison-Nozik, A., Anand, P., Zhu, H., Duan, Q., Sabeh, M., Prosdocimo, D. A., … Haldar, S. M. (2015). Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program. Proceedings of the National Academy of Sciences of the United States of America, 112(49), E6780–9. -
miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling.
Liu, X., Xiao, J., Zhu, H., Wei, X., Platt, C., Damilano, F., … Rosenzweig, A. (2015). miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metabolism, 21(4), 584–95. -
Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism.
Prosdocimo, D. A., Anand, P., Liao, X., Zhu, H., Shelkay, S., Artero-Calderon, P., … Haldar, S. M. (2014). Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. The Journal of Biological Chemistry, 289(9), 5914–24. -
Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation.
Haldar, S. M., Jeyaraj, D., Anand, P., Zhu, H., Lu, Y., Prosdocimo, D. A., … Jain, M. K. (2012). Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proceedings of the National Academy of Sciences of the United States of America, 109(17), 6739–44. -
Elevated fibroblast growth factor-2 increases tumor necrosis factor-alpha induced endothelial cell death in high glucose.
Clyne, A. M., Zhu, H., & Edelman, E. R. (2008). Elevated fibroblast growth factor-2 increases tumor necrosis factor-alpha induced endothelial cell death in high glucose. Journal of Cellular Physiology, 217(1), 86–92. -
A porous photocurable elastomer for cell encapsulation and culture.
Gerecht, S., Townsend, S. A., Pressler, H., Zhu, H., Nijst, C. L., Bruggeman, J. P., … Langer, R. (2007). A porous photocurable elastomer for cell encapsulation and culture. Biomaterials, 28(32), 4826–35. -
-
ACTN2 Mutations Are Associated With Cardiomyopathy and Cardiomyocyte Hypertrophy
Zhu, H., Ashley, E., & Wheeler, M. (2016). ACTN2 Mutations Are Associated With Cardiomyopathy and Cardiomyocyte Hypertrophy. CIRCULATION, 134. -
Computational Fluid Dynamics (BypassCFD) Trumps Anatomic Predictors of Saphenous Vein Graft Failure in CABG Patients
Kahn, O., Tran, J. S., Zhu, H., Packard, R. S., Karlsberg, R. P., Kahn, A., & Marsden, A. (2018). Computational Fluid Dynamics (BypassCFD) Trumps Anatomic Predictors of Saphenous Vein Graft Failure in CABG Patients. Circulation, 138(Suppl_1). -
Low Wall Shear Stress Is Associated with Saphenous Vein Graft Stenosis in Patients with Coronary Artery Bypass Grafting.
Khan, M. O., Tran, J. S., Zhu, H., Boyd, J., Packard, R. R., Karlsberg, R. P., … Marsden, A. L. (2020). Low Wall Shear Stress Is Associated with Saphenous Vein Graft Stenosis in Patients with Coronary Artery Bypass Grafting. Journal of Cardiovascular Translational Research. -
Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., … Wu, S. M. (2020). Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep, 22(5). -
Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.
Cheng, P., Zhu, H., Witteles, R. M., Wu, J. C., Quertermous, T., Wu, S. M., & Rhee, J.-W. W. (2020). Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Current Cardiology Reports, 22(5), 34. -
Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.
Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., … Wu, S. M. (2020). Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Current Cardiology Reports, 22(5), 36. -
Computational Fluid Dynamics (BypassCFD) Trumps Anatomic Predictors of Saphenous Vein Graft Failure in CABG Patients
Khan, M. O., Tran, J. S., Zhu, H., Packard, R. S., Karlsberg, R. P., Kahn, A., & Marsden, A. L. (2018). Computational Fluid Dynamics (BypassCFD) Trumps Anatomic Predictors of Saphenous Vein Graft Failure in CABG Patients. CIRCULATION, 138. -
Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Waliany, S., Galdos, F., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. Presented at the Basic Cardiovascular Sciences (BCVS) Scientific Sessions. -
A Case of Early Immune Checkpoint Inhibitor Myocarditis Detected on Routine Troponin Monitoring
Zhu, H., Waliany, S., Neal, J., Wakelee, H., Wu, S. M., & Witteles, R. M. (2020). A Case of Early Immune Checkpoint Inhibitor Myocarditis Detected on Routine Troponin Monitoring . Presented at the Advancing the Cardiovascular Care of the Oncology Patient. -
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany, S., Lee, D., Witteles, R. M., Neal, J. W., Nguyen, P., Davis, M. M., … Zhu, H. (2020). Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology. -
Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS. -
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39. -
Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
Asnani, A., Moslehi, J. J., Adhikari, B. B., Baik, A. H., Beyer, A. M., de Boer, R. A., … Zhu, H. (2021). Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. Circulation Research, RES0000000000000473. -
Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu, H., Ivanovic, M., Nguyen, A., Nguyen, P. K., & Wu, S. M. (2021). Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. Journal of Molecular and Cellular Cardiology. -
Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms.
Lindholm, M. E., Jimenez-Morales, D., Zhu, H., Seo, K., Amar, D., Zhao, C., … Wheeler, M. T. (2021). Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms. Circulation. Genomic and Precision Medicine, CIRCGEN121003419. -
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., … Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730. -
Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?
Katsumoto, T. R., Wilson, K. L., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., … Muppidi, S. (2022). Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity? Immunotherapy Advances, 2(1), ltac012. -
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.
Nowatzke, J., Guedeney, P., Palaskas, N., Lehmann, L., Ederhy, S., Zhu, H., … Salem, J.-E. E. (2022). Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. European Journal of Cancer (Oxford, England : 1990). -
LATE ONSET IMMUNOTHERAPY-INDUCED MYOCARDITIS TWO YEARS AFTER CHECKPOINT INHIBITOR INITIATION
Nguyen, A. T., Witteles, R. M., & Zhu, H. (2022). LATE ONSET IMMUNOTHERAPY-INDUCED MYOCARDITIS TWO YEARS AFTER CHECKPOINT INHIBITOR INITIATION. JACC: CardioOncology. -
devCellPy is a machine learning-enabled pipeline for automated annotation of complex multilayered single-cell transcriptomic data.
Galdos, F. X., Xu, S., Goodyer, W. R., Duan, L., Huang, Y. V., Lee, S., … Wu, S. M. (2022). devCellPy is a machine learning-enabled pipeline for automated annotation of complex multilayered single-cell transcriptomic data. Nature Communications, 13(1), 5271. -
Computational Fluid Dynamics of CABG Patients: CTA-derived Hemodynamic and Anatomic Predictors of Vein Graft Failure.
Kahn, M., Tran, J., Zhu, H., Packard, R., Karlsberg, R., & Marsden, A. (2019). Computational Fluid Dynamics of CABG Patients: CTA-derived Hemodynamic and Anatomic Predictors of Vein Graft Failure. Presented at the Society of Cardiovascular Computed Tomography. -
Characterization of Actin as a Cofactor for the Adenovirus Proteinase.
Zhu, H., McGrat, W., & Walter, M. (2007). Characterization of Actin as a Cofactor for the Adenovirus Proteinase. Presented at the Annual Research Exhibition at Brookhaven National Lab. -
Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation.
Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., & Zhu, H. (2022). Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation. JACC. CardioOncology, 4(5), 727–730. -
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity.
Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., … Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC. CardioOncology, 4(5), 629–634. -
The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis.
Zhu, H., Huang, Y. V., & Wu, S. M. (2023). The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis. Med (New York, N.Y.), 4(1), 13–14. -
Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer
Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., & Neal, J. W. (2023). Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. Jacc: CardioOncology, 5(1). -
Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., & Neal, J. W. (2023). Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. JACC. CardioOncology, 5(1), 85–98. -
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann, L. H., Heckmann, M. B., Bailly, G., Finke, D., Procureur, A., Power, J. R., … Salem, J.-E. E. (2023). Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis. Circulation. -
OSIMERTINIB-ASSOCIATED CARDIOMYOPATHY: A RETROSPECTIVE ANALYSIS OF THE STANFORD NON-SMALL CELL LUNG CANCER PATIENT COHORT
Franquiz, M., Witteles, R., Zhu, H., & Waliany, S. (2023). OSIMERTINIB-ASSOCIATED CARDIOMYOPATHY: A RETROSPECTIVE ANALYSIS OF THE STANFORD NON-SMALL CELL LUNG CANCER PATIENT COHORT. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
ACUTE CARDIOMYOPATHY AFTER INITIATION OF CABOZANTINIB, A MULTITYROSINE KINASE INHIBITOR
Cheng, E., & Zhu, H. (2023). ACUTE CARDIOMYOPATHY AFTER INITIATION OF CABOZANTINIB, A MULTITYROSINE KINASE INHIBITOR. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC. -
Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series
Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., … Zhu, H. (2023). Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. JACC: CardioOncology, 839–841. -
miR-222 inhibits pathological cardiac hypertrophyand heart failure.
Liu, X., Li, H., Hastings, M. H., Xiao, C., Damilano, F., Platt, C., … Rosenzweig, A. (2023). miR-222 inhibits pathological cardiac hypertrophyand heart failure. Cardiovascular Research. -
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine. -
Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine, 25(12), 715–735. -
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis (vol 29, pg 3100, 2023)
Fenioux, C., Abbar, B., Boussouar, S., Bretagne, M., Power, J. R., Moslehi, J. J., … Salem, J.-E. (2024). Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis (vol 29, pg 3100, 2023). NATURE MEDICINE. -
THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY
Ivanovic, M., Chan, A., Cheng, E., Xu, S., Lee, C., Franquiz, M., … Zhu, H. (2024). THE IMPACT OF ROUTINE CARDIAC TROPONIN I-BASED CARDIOTOXICITY SCREENING ON CLINICAL OUTCOMES IN PATIENTS ON CANCER IMMUNOTHERAPY. Biorxv. -
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.
Gergely, T. G., Drobni, Z. D., Kallikourdis, M., Zhu, H., Meijers, W. C., Neilan, T. G., … Varga, Z. V. (2024). Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure. Nature Reviews. Cardiology. -
A Novel Therapeutic Approach using CXCR3 Blockade to Treat Immune Checkpoint Inhibitor-mediated Myocarditis
Huang, Y. V., Lee, D., Sun, Y., Chou, H., Xu, B., Lin, Z., … Zhu, H. (2024). A Novel Therapeutic Approach using CXCR3 Blockade to Treat Immune Checkpoint Inhibitor-mediated Myocarditis. BioRxiv.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
General Cardiology Stanford, CA
Stanford, CA
General Cardiology
300 Pasteur Drive, 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Patient Reviews
(16 reviews)
Excellent medical care
Her post-visit notes were outstanding.
Great science, empathy and communication
Thank you for taking excellent care of my heart.
Thorough, explanatory. First meeting with her
Dr. Zhu is methodical in her questioning, and knowledgeable on my personal health issues.
She is a very professional, detail oriented, and knowledgable doctor.
She is wonderful to work with and communicates very clearly and to the point.
Very easy communication. She seems to enjoy her work and care about people. She is a very pleasant person.
Always the best care from Dr. Zhu and her team!
Excellent experience
Excellent video meeting.
Very professional and was spot on my case.
Dr. Zhu is professional, kind and caring and the new medication she prescribed to me gave me more energy and thanks a million for that.
Love Stanford healthcare always the best I have seen
Wonderful patient intake and office visit with this Doctor. Highly recommend.
Great doctor.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records